GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (FRA:AT2) » Definitions » Cyclically Adjusted PB Ratio

Atara Biotherapeutics (FRA:AT2) Cyclically Adjusted PB Ratio : 0.11 (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Cyclically Adjusted PB Ratio?

As of today (2024-04-30), Atara Biotherapeutics's current share price is €0.6458. Atara Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €6.15. Atara Biotherapeutics's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Atara Biotherapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:AT2' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.04   Med: 0.23   Max: 0.78
Current: 0.11

During the past years, Atara Biotherapeutics's highest Cyclically Adjusted PB Ratio was 0.78. The lowest was 0.04. And the median was 0.23.

FRA:AT2's Cyclically Adjusted PB Ratio is ranked better than
88.3% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs FRA:AT2: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Atara Biotherapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was €-0.855. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.15 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Atara Biotherapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Cyclically Adjusted PB Ratio Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.49 0.08

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.43 0.24 0.23 0.08

Competitive Comparison of Atara Biotherapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted PB Ratio falls into.



Atara Biotherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Atara Biotherapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.6458/6.15
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Atara Biotherapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.855/129.4194*129.4194
=-0.855

Current CPI (Dec. 2023) = 129.4194.

Atara Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.548 99.695 -0.711
201406 2.133 100.560 2.745
201409 -0.921 100.428 -1.187
201412 4.249 99.070 5.551
201503 6.418 99.621 8.338
201506 5.506 100.684 7.077
201509 10.498 100.392 13.533
201512 10.164 99.792 13.182
201603 9.546 100.470 12.297
201606 8.999 101.688 11.453
201609 8.347 101.861 10.605
201612 8.314 101.863 10.563
201703 7.488 102.862 9.421
201706 6.582 103.349 8.242
201709 5.648 104.136 7.019
201712 4.891 104.011 6.086
201803 8.115 105.290 9.975
201806 8.544 106.317 10.401
201809 7.567 106.507 9.195
201812 6.482 105.998 7.914
201903 5.426 107.251 6.548
201906 4.385 108.070 5.251
201909 5.342 108.329 6.382
201912 4.607 108.420 5.499
202003 3.882 108.902 4.613
202006 4.555 108.767 5.420
202009 3.891 109.815 4.586
202012 4.558 109.897 5.368
202103 3.987 111.754 4.617
202106 3.247 114.631 3.666
202109 2.983 115.734 3.336
202112 2.699 117.630 2.970
202203 2.181 121.301 2.327
202206 2.581 125.017 2.672
202209 1.992 125.227 2.059
202212 1.246 125.222 1.288
202303 0.628 127.348 0.638
202306 0.068 128.729 0.068
202309 -0.467 129.860 -0.465
202312 -0.855 129.419 -0.855

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atara Biotherapeutics  (FRA:AT2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Atara Biotherapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (FRA:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (FRA:AT2) Headlines

No Headlines